ABSTRACT
Adult patients with acute lymphoblastic leukemia (ALL) who are stratified into the standard risk (SR) group due to the absence of adverse prognostic factors relapse in 40-55% of the cases. To identify complementary markers suitable for further treatment stratification in SR ALL, we evaluated the predictive value of minimal residual disease (MRD) and prospectively monitored MRD in 196 strictly defined SR ALL patients at up to nine time-points during the first year of treatment by quantitative PCR. Frequency of MRD positivity decreased from 88% during early induction to 13% at week+52. MRD was predictive for relapse at various follow-up time-points.
Combined MRD information from different time-points allowed definition of three risk groups (p<0.001): 10% of patients with a rapid MRD decline to <10 -4 or below detection limit at day+11 and day+24 were classified as low-risk and had a 3-year relapse rate (RR) of 0%. A subset of 23% with until week+16 formed the high-risk group with a 3-year RR of 94% (95% CI 83-100%). The remaining patients whose RR was 47% (31-63%) represented the intermediate-risk group. Thus, MRD quantification during treatment identified prognostic subgroups within the otherwise homogeneous SR ALL population who may benefit from individualized treatment.
Introduction
Investigation of minimal residual disease (MRD) has been proven to be a valuable tool for predicting outcome in childhood acute lymphoblastic leukemia (ALL). [1] [2] [3] [4] [5] In contrast, only a few studies have focused on adult ALL and they were mostly based on patients with heterogeneous risk profiles and different kinds and intensities of treatment. [6] [7] [8] However, monitoring homogeneous patient cohorts at different timepoints during therapy might provide additional insight into the nature and clinical relevance of MRD kinetics in adult ALL which is particularly relevant for the large population of standard risk (SR) patients without conventional risk factors. Relapses in this patient group occur in about 40-55% of cases and cannot be predicted by any known conventional risk factor. [9] [10] [11] In a number of clinical studies this led to a policy of stem cell transplantation (SCT) in first remission [12] [13] [14] causing overtreatment and additional expenses for those patients who are cured by conventional chemotherapy alone. Therefore definition of prognostic factors allowing to discriminate SR patients with poor outcome after standard chemotherapy from those with a favorable prognosis is highly warranted. Currently the most widely used techniques to detect and quantify residual disease in patients with ALL are multiparameter immunophenotypic evaluation of aberrant protein expression 2; 3; 8 and clone-specific PCR amplification of immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements. 1; 4; 5 Such molecular targets can be identified in more than 90% of patients with ALL by the use of various PCR primer sets. Besides its large applicability and high sensitivity a main advantage of PCR based assays is the use of DNA as a stable and easy conveyable specimen which is particularly relevant in large multicenter studies. Until now, most molecular studies used semiquantitative or qualitative PCR methods for detection of Ig and TCR gene rearrangements. 1; 5-7 However, in adult ALL there is a high need for precise quantification to define For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From discriminating MRD levels at different sampling time-points, as MRD positivity is significantly more frequent in adults than in comparably treated children. 15; 16 Therefore, we and others have developed different immune gene real-time quantitative PCR (RQ-PCR) assays to permit accurate MRD quantification during the exponential phase of PCR amplification. [17] [18] [19] [20] [21] This allows the quantitative detection of one leukemic cell among 10000 normal cells with a good quality control, standardization and comparability of MRD data. Using these RQ-PCR assays, we conducted a prospective study on the predictive significance of MRD monitoring in adult SR ALL within the German Multicenter Study Group for Adult ALL (GMALL) trial with more than 100 participating centers that recruits more than 60% of the German incidence of adult ALL minimizing the risk of a selection bias and suggesting a high external validity. 22 Residual disease was sequentially monitored at multiple timepoints during therapy of 196 consecutive adults with standard risk ALL who were treated according to the GMALL 06/99 standard risk protocol. In a pilot study with 65 patients logistics and optimal sampling time-points as well as threshold levels were established.
For
METHODS

Patients
A total of 323 adults with ALL were included in the MRD trial at time of diagnosis. The study was divided into two phases: (1) A pilot phase within the GMALL 05/93 trial (January 1997-September 1999) to establish logistics, validate quantification methods and required sensitivities, define sampling time-points and MRD threshold levels (2) a main phase (October 1999-December 2002) to prospectively prove prognostic significance of MRD in strictly defined adult standard risk ALL patients who were consecutively enrolled in the GMALL 06/99 trial after written informed consent. Approval for these studies was obtained from the institutional review boards at each of the participating institutions.
The MRD pilot study comprised 71 adult ALL patients including 27 patients with highrisk features with available bone marrow samples at diagnosis and at up to six times during the first year of therapy (figure 1).
For the main GMALL 06/99 MRD trial, only standard risk ALL patients as defined by the following criteria were prospectively investigated: (A) absence of the translocations t(4;11)/MLL-AF4 and t(9;22)/BCR-ABL (B1) c-/pre-B-ALL with white blood cell (WBC) count <30000/Il at diagnosis or (B2) cortical-or mature-T-ALL with WBC count <100000/Il, since 2000 restriction to cortical-T-ALL irrespective of WBC count (C) age 15-65 years and (D) achievement of complete remission after phase I of induction therapy. Over the collection period, 291 consecutive GMALL 06/99 patients fulfilled inclusion criteria, bone marrow samples at diagnosis and at up to nine follow-up time-points during first year treatment were prospectively collected from 252 of these patients (87%). The nine bone marrow sampling times were defined according to fixed steps along the treatment protocol: mid-induction I (day+11), end of induction I (day+24), end of induction II (day+44), pre-consolidation For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From I (week+11) and II (week+16), pre-reinduction (week+22), pre-consolidation III (week+30) and V ( week+41) and end of first year of treatment (week+52) (figure 1). 33/252 patients had to be excluded due to an insufficient amount or quality of DNA in diagnostic and/or follow-up samples, therefore, molecular characterization of TCR-/Ig-rearrangement patterns was finally performed in 219 patients.
Treatment
In brief, GMALL 06/99 induction therapy phase I consisted of a six-drug regimen given over a period of three weeks with dexamethasone, cyclophosphamide, vincristine, daunorubicine, asparaginase, and intrathecal methotrexate. After Treatment elements in the GMALL 05/93 study were similar to the GMALL 06/99 protocol and are described elsewhere. 
Detection of residual disease
personal use only. on October 23, 2017. by guest www.bloodjournal.org From TaqMan probes (13 TCRB-J , 8 TCRG-V , 1 TCRD-J 1, 1 TCRD-D 2, 3 TCRD-V ,
Statistical analyses
Distribution of variables between groups was compared using Fisher`s exact test or
Chi-square test, the Mann Whitney U test was used to estimate significance of differences in continuous parameters. The end point to determine the prognostic significance of variables studied was the disease free survival (DFS), calculated as the interval between first documented complete remission and relapse or end of observation. Patients who underwent SCT in first remission (11 patients of the GMALL 06/99 trial), patients with premature termination of first year treatment (15 For personal use only. on October 23, 2017. by guest www.bloodjournal.org From GMALL 06/99 patients) and patients who died in complete remission (4 GMALL 06/99 patients) were included but censored at the date of event. Kaplan-Meier estimates were calculated for the time-to-event variables DFS and overall survival (OS). Comparison between curves was performed using the log-rank test, or the logrank test for linear trend in case of ordered categorical variables. 26 The influence of potential prognostic factors on DFS was estimated with the stepwise Cox proportional hazard model, including age, gender, WBC count, immunophenotype and MRD levels at different time-points.
All the statistical analyses were performed using the GraphPad Prism version 3.02 for windows (GraphPad Software, San Diego, CA, USA) and SPSS version 11.5 (SPSS Inc., Chicago, IL, USA). showed the strongest discriminative power after the end of induction I (day+24) until start of consolidation therapy (week+11) and was also used as cut-off point for week+16 to week+52. During induction I (day+11), MRD loads of greater than or equal to 10 -2 were associated with a 3.2 fold higher incidence of relapse than lower degrees or absence of detectable disease. A tumor load below detection limit (irrespective of target sensitivity) allowed a further substratification of patients with respect to a favorable outcome (see figure 3) . After the end of induction I (day+24), the relative risk for relapse in patients with MRD levels of 10 
Relation between residual disease on day 24 and MRD during consolidation therapy
Low or undetectable levels of day+24 MRD were related to MRD kinetics during later course of therapy. 105 patients were assayed at day+24, week+16 and beyond -4 ) or undetectable levels of day+11 and day+24 MRD formed the MRD-based low-risk group and had a 3-year DFS and OS rate of 100%.
Median follow-up of the patients was 33 (12 to 51) months. Pre-therapeutic clinical features were similar to that of the whole study population. No patient relapsed during the observation period, with one patient being censored after one year, as treatment was prematurely stopped prior to consolidation V due to severe treatment related complications. However, also this patient is still in complete remission after additional 15 months. 24 patients with MRD levels greater than or equal to 10 
DISCUSSION
The progress in treatment of adult ALL patients without conventional risk factors has been hampered by the inability to predict relapse after patients achieved a complete remission. Prospective MRD trials in large cohorts of homogeneously treated adult SR patients to define complementary prognostic markers are lacking. Within the GMALL 06/99 trial we were able to demonstrate that sequential monitoring of residual disease is a powerful indicator of treatment outcome. Using the combined information on day+11, day+24 and week+16 MRD, patients with a rapid tumor clearance and favorable outcome were discriminated from those with persistent disease and a particular high relapse rate (see figure 4) . Since MRD was monitored prospectively in the GMALL trial that includes more than 60% of the incidence of adult ALL years) in Germany and all patients without adverse conventional risk factors were intended to be investigated, a selection bias within the SR-ALL population was effectively minimized. The definition of adverse factors emerged from the more than 3000 adult ALL patients homogeneously treated in the GMALL trials over a period of 20 years. 9 The 3-year relapse rate of 47% in our SR-ALL study population was in keeping with the results of other adult ALL trials, 9 and relapses were not predictable by conventional clinical and biological factors. Therefore, the only known variable potentially influencing outcome in the study population was MRD.
With regard to MRD kinetics, frequency of MRD positivity tended to be higher than reported for childhood ALL. In our study 63% of adult patients had measurable MRD at day+24 and 47% at day+44, whereas in five large prospective studies on childhood ALL, residual disease was detectable in 25% to 58% of patients after four to six weeks of induction therapy. 1; 4; 5 Also at later time-points, percentage of MRD positivity in adult patients was higher. MRD was detected in 23% of cases at week+30, compared to only 10-13% of pediatric ALL. [1] [2] [3] [4] [5] This probably reflects the higher in vivo drug resistance of adult ALL and was also reported by Mortuza et al.. 7 MRD quantification during induction (day+11) identified patients with a very rapid molecular response and an excellent prognosis (3-year DFS 92%) in line with reports on childhood ALL. 27; 28 Also the extent of residual disease after induction therapy predicted treatment outcome, although patients who reached the condition of MRD clearance down to In our study, post-induction MRD provided important information by identifying patients with an extremely poor prognosis. Single MRD tests at week+16 and week+22 narrowed a population of 38/148 patients (26%) and 25/126 patients (20%), respectively, with a 3-year DFS of 12%. This is in keeping with findings of Vidriales et al. 8 in an immunophenotypic analysis on 102 adolescent and adult ALL patients who demonstrated a high discriminative power of day+35 MRD but a relapse rate of about 50% even in patients with MRD levels <0·05%. Similarly, Brisco et al. 15 analyzed MRD in 27 adults by PCR reporting that 8/11 patients (73%) with MRD >10 -3 relapsed compared to 6/16 (38%) with MRD <10 -3 after the end of induction (day+22 to +68). Mortuza and colleagues DFS for patients with detectable MRD 3-5 months and 6-9 months after diagnosis, was 11% and 0%, respectively, as compared to 74% and 80% in MRD-negative patients.
Molecular MRD assessment using Ig-/TCR-gene rearrangements as PCR targets might be hampered by the occurrence of continuing rearrangements. 29 In our study population this is the most likely explanation for false negative PCR results in 11% of the investigated samples obtained at relapse and stresses the importance of the use of two molecular targets for MRD quantification. However, results of different trials are not fully conclusive [33] [34] [35] [36] and comparability of data is hampered, as we exclusively investigated standard risk patients.
In this study we have shown, that molecular MRD quantification in adult ALL is feasible even in large multicenter studies. Early MRD assessment allowed the identification of patients with a high chance for cure by chemotherapy alone, persistent detectable disease 10 -4 during consolidation was associated with a high risk of relapse. Therefore, day+11 and week+16 MRD information was adducted to define an MRD-based low-(day+11) and high-(week+16) risk group. To enhance accuracy for MRD-based risk-stratification, results were approved by a second MRD test (day+24). This stratification was applicable to 105 patients who did not differ in For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From presenting features from the group of patients without MRD measurement at crucial time-points. The relatively high percentage of exclusions due to missing samples is explainable by the fact that this was the first prospective MRD trial within the GMALL studies checking a considerable number of follow-up time-points and recruiting patients of more than 100 participating centers. The fraction of evaluable patients was comparable to the results of the first large prospective MRD studies on pediatric ALL. [1] [2] [3] [4] [5] However, looking at the distribution of MRD-based risk groups, percentages substantially differed: In pediatric patients MRD-defined low-risk groups made up for 40% to 90% of patients whereas only 5% to 15% of patients belonged to the MRDbased high-risk groups. 1-3;5 Probably differences would have been even more pronounced if adult patients with high-risk features were added into our analysis because median MRD levels in high-risk ALL appear to exceed that of standard risk ALL 5; 8; 37 as also the results of the GMALL 05/93 MRD pilot study indicate. The small size of the MRD-based low-risk group in our study compared to pediatric trials might reflect differences in biology of the disease, as even SR ALL in adults has a much poorer prognosis than childhood ALL. In addition, we applied extremely strict criteria to define the MRD-based low-risk group as specific as possible, accepting a loss of sensitivity, in order to minimize the risk of relapse for the individual patient being assigned to the MRD-based low-risk group. The fraction of patients that belongs to the MRD-based intermediate-risk group is higher compared to childhood ALL.
Although these patients will receive standard therapy further on they might profit from establishment of patient specific MRD assays as they can easily be monitored during and after maintenance therapy. Whether a disease recurrence can be identified in time to allow early intervention prior to a clinical relapse is currently prospectively analyzed.
The type of the treatment protocol, timing of the follow-up samples and the applied MRD technique might influence the definition of the MRD-based risk-groups.
Therefore, precise MRD-threshold levels for risk-group assignment have to be defined carefully for each treatment protocol before MRD-based risk-stratification can be implemented. For personal use only. 
